HC Wainwright & Co. Downgrades TCR2 Therapeutics to Neutral
HC Wainwright & Co. analyst Robert Burns downgrades TCR2 Therapeutics (NASDAQ:TCRR) from Buy to Neutral.
BMO Capital Downgrades Ovintiv to Market Perform, Lowers Price Target to $51
BMO Capital analyst Phillip Jungwirth downgrades Ovintiv (NYSE:OVV) from Outperform to Market Perform and lowers the price target from $56 to $51.
Jefferies Downgrades Radius Global Infr to Hold, Raises Price Target to $15
Jefferies analyst Jonathan Petersen downgrades Radius Global Infr (NASDAQ:RADI) from Buy to Hold and raises the price target from $14 to $15.
Goldman Sachs Downgrades Artisan Partners Asset to Sell, Announces $27 Price Target
Goldman Sachs analyst Alexander Blostein downgrades Artisan Partners Asset (NYSE:APAM) from Neutral to Sell and announces $27 price target.
William Blair Downgrades Qualtrics International to Market Perform
William Blair analyst Bhavan Suri downgrades Qualtrics International (NASDAQ:XM) from Outperform to Market Perform.
Arete Research Downgrades Meta Platforms to Sell
Arete Research analyst Richard Kramer downgrades Meta Platforms (NASDAQ:META) from Neutral to Sell.
R5 Capital Downgrades Sprouts Farmers Market to Hold
R5 Capital analyst Scott Mushkin downgrades Sprouts Farmers Market (NASDAQ:SFM) from Buy to Hold.
Vertical Research Downgrades Embark Technology to Hold, Announces $4 Price Target
Vertical Research analyst Jeffrey Kauffman downgrades Embark Technology (NASDAQ:EMBK) from Buy to Hold and announces $4 price target.
Wedbush Downgrades Allbirds to Neutral, Announces $3 Price Target
Wedbush analyst Tom Nikic downgrades Allbirds (NASDAQ:BIRD) from Outperform to Neutral and announces $3 price target.
Northcoast Research Downgrades Wendy’s to Neutral
Northcoast Research analyst Jim Sanderson downgrades Wendy's (NASDAQ:WEN) from Buy to Neutral.